Vanguard Global Advisers’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Vanguard Global Advisers's CTKB Position: Q3 2026 in Review
Vanguard Global Advisers increased its Cytek Biosciences (CTKB) stake by 1.3% in Q3 2026, buying an estimated $2.88K and bringing the position to 45,819 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2350.
Vanguard Global Advisers first reported a position in CTKB in Q1 2026 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Vanguard Global Advisers held 45,819 shares of Cytek Biosciences worth $273K as of Q3 2026.
- Vanguard Global Advisers bought 607 Cytek Biosciences shares in Q3 2026, an estimated $2.88K.
- Cytek Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2350 holding.
- Vanguard Global Advisers first reported a position in Cytek Biosciences in Q1 2026 and has held it in 3 quarters since.
- 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.